{
    "clinical_study": {
        "@rank": "161457", 
        "acronym": "DAHHS", 
        "arm_group": {
            "arm_group_label": "Boceprevir", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Prospective open label proof of concept feasibility interventional clinical trial in which\n      60 acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in\n      addition to Standard Of Care Peginterferon + Ribavirin if they show a Rapid Viral Responds\n      at week 4.\n\n      The primary hypothesis of this study is that the subset of patients with a Rapid Viral\n      Responds after 4 weeks of triple therapy with boceprevir, peginterferon alpha-2b (P) and\n      ribavirin (RVR4) can be successfully treated with a shorter 12-week triple therapy regimen."
        }, 
        "brief_title": "Dutch Acute HCV in HIV Study (DAHHS)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis C", 
            "Human Immunodeficiency Virus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Documented recent HCV genotype 1 infection (\u226426 weeks old at the time of the baseline\n             visit) according to definition mentioned below.\n\n          2. Plan to start a Standard Of Care therapy for acute HCV consisting of 24 weeks of\n             Peginterferon + Ribavirin. HCV RNA plasma viral load at screening >1000 IU/ml.\n\n          3. A previously performed HCV RNA plasma measurement can be used for screening if <4\n             weeks old.\n\n          4. On HAART at the time of screening.\n\n          5. Minimum age 18 years.\n\n        Exclusion Criteria:\n\n          1. Disallowed co-medication that cannot be stopped or replaced: Several potentially\n             life-threatening drug-drug interactions (DDI) are possible when boceprevir is\n             combined with other drugs. Therefore ALL co-medication, including over-the-counter\n             drugs should be checked for potential DDI with DDI table in the Dutch summary of\n             product characteristics (SPC, appendix A). If the co-medication is not mentioned in\n             the SPC DDI table, www.HCV-druginteractions.org should be used.\n\n          2. Contraindications for the use of full dose of peginterferon alpha-2b or ribavirin:\n             neutrophils <0,75\u00d7109/l or thrombocytes < 100.000\u00d7109/l or a Hb <6.2mmol/L,\n             creatinine clearance <50ml/min).\n\n          3. History of liver cirrhosis or >F1 fibrosis on fibroscan. Inclusion of patients with a\n             chronic well-controlled HBV (HBV-DNA below the limit of detection) with tenofovir,\n             lamivudine or emtricitabine therapy is allowed if fibroscan excludes >F1 fibrosis.\n             Fibroscan reports <2 years old can be used for screening. Fibroscan is not required\n             for other patients at screening.\n\n          4. HAART was started <4 weeks before baseline visit.\n\n          5. Inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse\n             transcriptase inhibitors + Raltegravir (Isentress\u00ae) 400mg BID or rilpivirine 25mg QD\n             or atazanavir (Reyataz\u00ae) 300mg QD + ritonavir (Norvir\u00ae) 100mg QD.\n\n          6. Patient that virologically failed HAART in the past"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912495", 
            "org_study_id": "NL44825.078.13"
        }, 
        "intervention": {
            "arm_group_label": "Boceprevir", 
            "intervention_name": "Boceprevir", 
            "intervention_type": "Drug", 
            "other_name": "Victrelis"
        }, 
        "intervention_browse": {
            "mesh_term": "Peginterferon alfa-2b"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "m.claassen@erasmusmc.nl", 
                    "last_name": "Mark Claassen, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "state": "Zuid Holland", 
                        "zip": "3000CA"
                    }, 
                    "name": "Erasmus MC"
                }, 
                "investigator": [
                    {
                        "last_name": "Bart Rijnders, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Marc Claassen", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Bas Hullegie", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "G.E.L.vandenBerk@olvg.nl", 
                    "last_name": "Guido Van den Berk", 
                    "phone": "0031 205993501"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "OLVG"
                }, 
                "investigator": {
                    "last_name": "Guido Van den Berk", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "j.t.vandermeer@amc.uva.nl", 
                    "last_name": "Jan van der Meer", 
                    "phone": "0031 205669111"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "AMC"
                }, 
                "investigator": {
                    "last_name": "Jan van den Meer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Fanny.lauw@slz.nl", 
                    "last_name": "Fanny Lauw"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Slotervaart"
                }, 
                "investigator": {
                    "last_name": "Fanny lauw", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "crichter@rijnstate.nl", 
                    "last_name": "Clemens Richter"
                }, 
                "facility": {
                    "address": {
                        "city": "Arnhem", 
                        "country": "Netherlands"
                    }, 
                    "name": "Ziekenhuis Rijnstate"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "w.f.w.bierman@umcg.nl", 
                    "last_name": "Wouter Bierman"
                }, 
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands"
                    }, 
                    "name": "UMCG"
                }, 
                "investigator": {
                    "last_name": "Sander van Assen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "d.posthouwer@mumc.nl", 
                    "last_name": "dirk posthouwer"
                }, 
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands"
                    }, 
                    "name": "MUMC"
                }, 
                "investigator": {
                    "last_name": "dirk posthouwer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "p.koopmans@aig.umcn.nl", 
                    "last_name": "Peter Koopmans", 
                    "phone": "0031243616498"
                }, 
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands"
                    }, 
                    "name": "Radboud UMCN"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "j.e.arends@umcutrecht.nl", 
                    "last_name": "Joop Arends", 
                    "phone": "0031 88 7555555", 
                    "phone_ext": "1180"
                }, 
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands"
                    }, 
                    "name": "UMCU"
                }, 
                "investigator": {
                    "last_name": "Joop Arends", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial.", 
        "overall_contact": {
            "email": "b.hullegie@erasmusmc.nl", 
            "last_name": "Bas Hullegie, MD", 
            "phone": "+31613088212"
        }, 
        "overall_contact_backup": {
            "email": "b.rijnders@erasmusmc.nl", 
            "last_name": "Bart Rijnders, MD, PhD", 
            "phone": "+31107033510"
        }, 
        "overall_official": {
            "affiliation": "Erasmus MC", 
            "last_name": "Bart Rijnders, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sustained Viral Responds(SVR) at 24 weeks of follow up after the end of all therapy for the Rapid Viral Response at week 4(RVR4) population.", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912495"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Erasmus Medical Center", 
            "investigator_full_name": "Bart Rijnders", 
            "investigator_title": "MD,PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "SVR 24 weeks after the end of all therapy in the entire study population (with or without RVR4).", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "SVR 12 weeks after end of therapy in RVR4 population.", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "SVR 24 weeks after end of therapy in patients with already a RVR at week 1.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "SVR 24 weeks after end of therapy in patients that started therapy \u226412weeks after the presumed HCV infection date versus those after 12 weeks.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Alterations of biomarkers by therapy induced viral eradication: Viral sequencing, mutation analysis, gene expression analysis, and RNA analysis.", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "measure": "Safety: Treatment related (serious) adverse events ((S)AE) and treatment discontinuation for (S)AE.", 
                "safety_issue": "Yes", 
                "time_frame": "72 weeks"
            }
        ], 
        "source": "Erasmus Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Onze Lieve Vrouwe Gasthuis", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "UMC Utrecht", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Medical Centre Groningen", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Maastricht University Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Rijnstate Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Slotervaart Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "UMCN", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Erasmus Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}